Cantor Fitzgerald launched coverage of SELLAS Life Sciences (NASDAQ:SLS) with an “outperform” rating and $18 price target. The stock closed at $8.60 on July 20. SELLAS is a late-stage immune-oncology company that is...
SELLAS Life Sciences (NASDAQ:SLS) reported final follow-up data from its Phase 1/2 study of galinpepimut-S in patients with acute myeloid leukemia (AML) in second complete remission. The data demonstrate a median...
Maxim Group upgraded SELLAS Life Sciences (NASDAQ:SLS) to “buy” from “hold” with a price target of $12 after the company removed a financing overhang. The stock closed at $6.17 on Nov. 14. SELLAS ended the latest...
SELLAS Life Sciences Group (NASDAQ:SLS) completed enrollment for a Phase 2 study of nelipepimut-S (NPS) in combination with granulocyte macrophage colony stimulating factor (GM-CSF) in women with ductal carcinoma in...
SELLAS Life Sciences Group (NASDAQ:SLS) and Memorial Sloan Kettering Cancer Center will conduct a Phase 1 study of SELLAS’ galinpepimut-S (GPS) in combination with nivolumab in patients with relapsed or refractory...
Maxim Group upgraded Sellas Life Sciences (NASDAQ:SLS) to “buy” from “hold,” with a $13 price target after meeting with Sellas management. The stock closed at $4.79 on March 16. Sellas completed a merger with Galena...